Trial Information
Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
Inclusion Criteria:
- Patient with Cushing's disease uncured biochemically after pituitary surgery with
adenoma on histopathology
Exclusion Criteria:
- Patient's intolerance to drug or known sensitivity to ergot derivatives
- Pregnancy, lactation or female wishing to be pregnant
- Any serious medical illness
- Patient on any drugs known to have an interaction with cabergoline including
antihypertensives like reserpine and methyl dopa, neuroleptics, metoclopramide, etc
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Response in term of mid night cortisol < 5.0 mcg/dl and/or Standard two day dexamethasone suppression test < 1.8 mcg/dl
Principal Investigator
Nalini S Shah, DM
Investigator Role:
Principal Investigator
Investigator Affiliation:
Seth GSMC and KEM hospital, Mumbai
Authority:
India: Drugs Controller General of India
Study ID:
EC/104/2005
NCT ID:
NCT00889525
Start Date:
November 2007
Completion Date:
Related Keywords:
- Cushing's Disease
- Corticotroph Adenoma
- Cabergoline
- Adenoma
- Cushing Syndrome
- Pituitary ACTH Hypersecretion
- Pituitary Neoplasms
- ACTH-Secreting Pituitary Adenoma